Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Advisory Council April 2018 Meeting Presentation: ADRD Research Update

Friday, April 27, 2018

Printer Friendly Version in PDF Format (11 PDF pages)


Alzheimer's Disease and Related Dementias Research Update

Richard Hodes, M.D.
Director, NIA


  • 2011: The National Alzheimer's Project Act (NAPA) was signed into law in January -- updated annually
  • 2012: $50 M* redirected as part of Presidential initiative
  • 2013: $40 M* redirected from unallocated funds in the NIH budget
  • 2014: $100 M in additional appropriations
  • 2015: $25 M in additional appropriations
  • 2016: $350 M in additional appropriations
  • 2017: $400 M in additional appropriations
  • 2018: $414 M in additional appropriations as of 3/23/18

*one-year money
Years displayed are Fiscal Years

NIA Appropriations

Fiscal Years 2013-2018
Bar chart: 2013 ($1,046), 2014 ($1,172), 2015 ($1,198), 2016 ($1,596), 2017 ($2,049), 2018 ($2,574).


AD/ADRD Research Implementation Milestones and Bypass Budget Process

NIH Research Implementation Milestones are Based on Broad Input

  • 2011: The National Alzheimer's Project Act (NAPA) was signed into law in January -- updated annually
  • 2012: AD Summit
  • 2013: ADRD Summit
  • 2015: AD Summit
  • 2016: ADRD Summit
  • 2017: AD Care/Services Summit [Newest sources of milestone input]
  • 2018: AD Summit [Newest sources of milestone input]
  • 2019: ADRD Summit
  • 2020: AD Care/Services Summit

What Counts as AD/ADRD Research?

  • The AD/ADRD payline applies to applications/awards that are coded as AD or Alzheimer's disease- related dementias (ADRD)
  • The ADRD RCDC categories that report related dementias specifically named in the National Plan to Address Alzheimer's Disease are:
    • Lewy Body dementia (LBD)
    • Frontotemporal dementia (FTD)
    • Vascular Cognitive Impairment/Dementia (VCI/D)

Combined External and Internal Input -- FY20 AD/ADRD Bypass Budget

  • Input at 2012-2018 meetings:
    • Academic research community
    • Industry
    • Non-governmental organizations
  • Other Input:
    • 2017 Request for Information
  • Development of comprehensive milestones (NIH staff) -- based on summit and other input
  • Trans-NIH (including NINDS) staff discussion; milestones edited to ensure comprehensive inclusion of priorities for FY20
  • NIH staff "price" the milestones
  • Final budget estimate for FY20

Timing of ADBB Releases and AD/ADRD Appropriations

  • FY17 AD/ADRD milestones -- $323M extra needed
    • FY17 ADBB Released July 2015
    • $350M in FY16 supports acceleration of FY17 milestones
  • FY18 AD/ADRD milestones - $414M extra needed
    • FY18 ADBB Released August 2016
    • $400M in FY17 supports acceleration of FY18 milestones
  • FY19 AD/ADRD milestones - $597M extra needed
    • FY19 ADBB Released July 2017
    • $414M in FY18 supports acceleration of FY19 milestones
  • FY20 ADBB: release planned July 2018

Complex Considerations for Future Bypass Budgets

  • Past/current appropriations, including funds that have allowed us to address milestones "in advance"
  • Progress on milestones -- what have we accomplished? what new milestones are emerging?
  • Incorporating new care/services research milestones along with other milestones that are focused on drug development, etc.
  • Large project needs -- emerging clinical trials, etc.
  • Emerging investments by other groups -- what gaps are best filled by the NIA/NIH?
  • Successes in recruiting new and established researchers to AD/ADRD research and capacity of the field


NIA-Alzheimer's Association Research Framework

NIA-AA Research Framework

A-T-(N)- Normal Alzheimer's biomarkers  
A+T-(N)- Alzheimer's pathologic change Alzheimer's continuum
A+T+(N)- Alzheimer's disease
A+T+(N)+ Alzheimer's disease
A+T-(N)+ Alzheimer's and suspected non-Alzheimer's pathologic change
A-T+(N)- Non-Alzheimer's pathologic change  
A-T-(N)+ Non-Alzheimer's pathologic change  
A-T+(N)+ Non-Alzheimer's pathologic change  
A = Amyloid; T = Tau; N = Neurodegeneration
Adapted from Jack et al., Alzheimer's & Dementia (2018) 14(4): 535-562.

The framework will hopefully aid researchers in identifying individuals at risk for disease sufficiently early to test new prevention strategies as they emerge

Framework for 0 to over 80 years of age.
Silverberg et al., Alzheimer's & Dementia (2018) 14(4):576-578.


Summit Updates

National Research Summit on Care, Services and Supports for Persons with Dementia and Their Caregivers

Save the Date

  • AD/ADRD Care/Services Summit (II)
  • March 24-25, 2020
  • Natcher Conference Center, Bethesda, MD

NEW Planned Evidence Review: Care Interventions for Individuals with Dementia and Their Caregivers

  • Hundreds of studies have looked at the efficacy and effectiveness of care/caregiving interventions, but what is the quality of evidence supporting readiness for dissemination of any of these?
  • NIA is funding a two-part study similar to that used for the recent dementia prevention literature review
  • Initial steps:
    • National Academies of Sciences, Engineering, and Medicine: Expert panel input on questions and study design
    • Agency for Healthcare Research & Quality: Evidence review
  • Draft study questions, and other planned study parameters will be posted for public comment
    • The URL will be shared widely once available

NIH AD Research Summits: Path to Treatment and Prevention

  • Dates:
    • May 14-15, 2012
    • Feb 9-10, 2015
    • March 1-2, 218
  • Goal: The 2018 Summit was built on the foundation laid by the NIH AD Research Summits held in 2012 and 2015. It featured progress towards achieving the AD research implementation milestones and continue development of an integrated multidisciplinary research agenda necessary to enable precision medicine for AD.

AD Research Summit Program

  • The Summit Program was organized around 7 sessions and featured 86 speaker
    1. Novel Mechanistic Insights into the Complex Biology and Heterogeneity of AD
    2. Enabling Precision Medicine for AD
    3. Translational Tools and Infrastructure to Enable Predictive Drug Development
    4. Emerging Therapeutics
    5. Understanding the Impact of the Environment to Advance Disease Prevention
    6. Advances in Disease Monitoring, Assessment and Care
    7. Building an Open Science Research Ecosystem to Accelerate AD Therapy Development
  • Central programmatic themes of the 2018 Summit:
    • Understanding disease heterogeneity
    • Enhancing research rigor, reproducibility and translatability
    • Enabling rapid translational learning through open science systems and incentives.

AD Research Summit Program

Additional Save the Date

  • ADRD Summit (III)
  • March 14-15, 2019
  • Bethesda, MD

Co-hosted by the NIA.

April 27, 2018 -- Advisory Council Meeting #28

The meeting was held on Friday, April 27, 2018, in Washington, DC. During the meeting, the Clinical Care Subcommittee took charge of the theme, focusing on advancing consensus on dementia care elements to guide new outcomes measurement. The Council heard speakers in two sessions, one focused on developing consensus about dementia care elements, and the second on models that are informing outcomes measurement. The meeting also included updates on work from the previous meetings, a presentation on the final report from the October 2017 Care Summit, and federal workgroup updates. Material available from this meeting is listed below or at

Comments and questions, or alerts to broken links, should be sent to


General Information



  • Main Summit Recommendations -- [HTML Version] [PDF Version]

  • National Research Summit on Care, Services, and Supports for Persons with Dementia and Their Caregivers: Report to the National Advisory Council on Alzheimer's Research, Care, and Services -- [HTML Version] [PDF Version]


Presentation Slides



  • Introductions and Updates -- [Video]

  • Clinical Care Agenda Session 1 -- [Video]

  • Public Comments -- [Video]

  • Clinical Care Agenda Session 2 -- [Video]

  • Care Summit Final Report -- [Video]

  • MEETING WRAP-UP: Final Report to the NAPA Advisory Council -- [Video]